Advanced Oncotherapy PLC (AVO) Rating Reiterated by Beaufort Securities
Advanced Oncotherapy PLC (LON:AVO)‘s stock had its “speculative buy” rating reiterated by research analysts at Beaufort Securities in a note issued to investors on Monday.
Shares of Advanced Oncotherapy PLC (LON:AVO) opened at 109.37 on Monday. Advanced Oncotherapy PLC has a 12 month low of GBX 98.00 and a 12 month high of GBX 217.25. The firm’s market cap is GBX 62.05 million. The firm has a 50-day moving average of GBX 119.96 and a 200-day moving average of GBX 147.34.
In related news, insider Bradfield ,Michael bought 30,000 shares of the company’s stock in a transaction on Monday, July 11th. The shares were purchased at an average cost of GBX 135 ($1.76) per share, for a total transaction of £40,500 ($52,865.16).
Advanced Oncotherapy PLC Company Profile
Advanced Oncotherapy Plc is a United Kingdom-based company. The Company is engaged in providing medical technology for cancer treatment and managing a health-related property. The Company operates in three business segments: Proton Therapy, Single Dose Intra-Operative Radiotherapy Treatment (SDIORT) and Healthcare related properties.
Receive News & Stock Ratings for Advanced Oncotherapy PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy PLC and related stocks with our FREE daily email newsletter.